<scp>Cost‐effectiveness</scp> of <scp>second‐line</scp> empagliflozin versus liraglutide for type 2 diabetes in the United States

Abstract

For patients with T2D, use of second-line empagliflozin combined with metformin was a dominant strategy for US payers, associated with extended survival, improved QALYs, and lower costs compared with second-line liraglutide.